Medios AG
Medios AG (MEDOF) Stock Competitors & Peer Comparison
See (MEDOF) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Distribution Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MEDOF | $50.00 | +0.00% | 1.2B | 73.53 | $0.68 | N/A |
| SHPMF | $1.46 | +0.00% | 8.5B | 6.64 | $0.22 | +3.93% |
| SHTDY | $12.50 | +0.77% | 7.7B | 7.32 | $1.68 | +3.69% |
| SHTDF | $2.30 | -11.54% | 7.2B | 6.76 | $0.34 | +4.11% |
| GALNF | $115.00 | +0.00% | 5.7B | 24.57 | $4.68 | +2.29% |
| SHPMY | $7.60 | +0.00% | 5.6B | 6.73 | $1.13 | +3.77% |
| CAKFY | $4.10 | +0.00% | 5.4B | -68.33 | -$0.06 | N/A |
| MAHLY | $19.10 | +0.00% | 3.9B | 15.53 | $1.23 | +1.70% |
| MEPDF | $19.00 | +0.00% | 3.9B | 15.45 | $1.23 | +2.19% |
| ALFRY | $16.81 | +0.00% | 3.1B | 19.78 | $0.85 | +2.63% |
Stock Comparison
MEDOF vs SHPMF Comparison April 2026
MEDOF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDOF stands at 1.2B. In comparison, SHPMF has a market cap of 8.5B. Regarding current trading prices, MEDOF is priced at $50.00, while SHPMF trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDOF currently has a P/E ratio of 73.53, whereas SHPMF's P/E ratio is 6.64. In terms of profitability, MEDOF's ROE is +0.04%, compared to SHPMF's ROE of +0.08%. Regarding short-term risk, MEDOF is more volatile compared to SHPMF. This indicates potentially higher risk in terms of short-term price fluctuations for MEDOF.Check SHPMF's competition here
MEDOF vs SHTDY Comparison April 2026
MEDOF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDOF stands at 1.2B. In comparison, SHTDY has a market cap of 7.7B. Regarding current trading prices, MEDOF is priced at $50.00, while SHTDY trades at $12.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDOF currently has a P/E ratio of 73.53, whereas SHTDY's P/E ratio is 7.32. In terms of profitability, MEDOF's ROE is +0.04%, compared to SHTDY's ROE of +0.09%. Regarding short-term risk, MEDOF is more volatile compared to SHTDY. This indicates potentially higher risk in terms of short-term price fluctuations for MEDOF.Check SHTDY's competition here
MEDOF vs SHTDF Comparison April 2026
MEDOF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDOF stands at 1.2B. In comparison, SHTDF has a market cap of 7.2B. Regarding current trading prices, MEDOF is priced at $50.00, while SHTDF trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDOF currently has a P/E ratio of 73.53, whereas SHTDF's P/E ratio is 6.76. In terms of profitability, MEDOF's ROE is +0.04%, compared to SHTDF's ROE of +0.09%. Regarding short-term risk, MEDOF is more volatile compared to SHTDF. This indicates potentially higher risk in terms of short-term price fluctuations for MEDOF.Check SHTDF's competition here
MEDOF vs GALNF Comparison April 2026
MEDOF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDOF stands at 1.2B. In comparison, GALNF has a market cap of 5.7B. Regarding current trading prices, MEDOF is priced at $50.00, while GALNF trades at $115.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDOF currently has a P/E ratio of 73.53, whereas GALNF's P/E ratio is 24.57. In terms of profitability, MEDOF's ROE is +0.04%, compared to GALNF's ROE of +0.12%. Regarding short-term risk, MEDOF is more volatile compared to GALNF. This indicates potentially higher risk in terms of short-term price fluctuations for MEDOF.Check GALNF's competition here
MEDOF vs SHPMY Comparison April 2026
MEDOF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDOF stands at 1.2B. In comparison, SHPMY has a market cap of 5.6B. Regarding current trading prices, MEDOF is priced at $50.00, while SHPMY trades at $7.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDOF currently has a P/E ratio of 73.53, whereas SHPMY's P/E ratio is 6.73. In terms of profitability, MEDOF's ROE is +0.04%, compared to SHPMY's ROE of +0.08%. Regarding short-term risk, MEDOF is more volatile compared to SHPMY. This indicates potentially higher risk in terms of short-term price fluctuations for MEDOF.Check SHPMY's competition here
MEDOF vs CAKFY Comparison April 2026
MEDOF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDOF stands at 1.2B. In comparison, CAKFY has a market cap of 5.4B. Regarding current trading prices, MEDOF is priced at $50.00, while CAKFY trades at $4.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDOF currently has a P/E ratio of 73.53, whereas CAKFY's P/E ratio is -68.33. In terms of profitability, MEDOF's ROE is +0.04%, compared to CAKFY's ROE of -0.02%. Regarding short-term risk, MEDOF is more volatile compared to CAKFY. This indicates potentially higher risk in terms of short-term price fluctuations for MEDOF.Check CAKFY's competition here
MEDOF vs MAHLY Comparison April 2026
MEDOF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDOF stands at 1.2B. In comparison, MAHLY has a market cap of 3.9B. Regarding current trading prices, MEDOF is priced at $50.00, while MAHLY trades at $19.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDOF currently has a P/E ratio of 73.53, whereas MAHLY's P/E ratio is 15.53. In terms of profitability, MEDOF's ROE is +0.04%, compared to MAHLY's ROE of +0.07%. Regarding short-term risk, MEDOF is more volatile compared to MAHLY. This indicates potentially higher risk in terms of short-term price fluctuations for MEDOF.Check MAHLY's competition here
MEDOF vs MEPDF Comparison April 2026
MEDOF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDOF stands at 1.2B. In comparison, MEPDF has a market cap of 3.9B. Regarding current trading prices, MEDOF is priced at $50.00, while MEPDF trades at $19.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDOF currently has a P/E ratio of 73.53, whereas MEPDF's P/E ratio is 15.45. In terms of profitability, MEDOF's ROE is +0.04%, compared to MEPDF's ROE of +0.07%. Regarding short-term risk, MEDOF is more volatile compared to MEPDF. This indicates potentially higher risk in terms of short-term price fluctuations for MEDOF.Check MEPDF's competition here
MEDOF vs ALFRY Comparison April 2026
MEDOF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDOF stands at 1.2B. In comparison, ALFRY has a market cap of 3.1B. Regarding current trading prices, MEDOF is priced at $50.00, while ALFRY trades at $16.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDOF currently has a P/E ratio of 73.53, whereas ALFRY's P/E ratio is 19.78. In terms of profitability, MEDOF's ROE is +0.04%, compared to ALFRY's ROE of +0.07%. Regarding short-term risk, MEDOF is more volatile compared to ALFRY. This indicates potentially higher risk in terms of short-term price fluctuations for MEDOF.Check ALFRY's competition here
MEDOF vs AMFPF Comparison April 2026
MEDOF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDOF stands at 1.2B. In comparison, AMFPF has a market cap of 2.2B. Regarding current trading prices, MEDOF is priced at $50.00, while AMFPF trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDOF currently has a P/E ratio of 73.53, whereas AMFPF's P/E ratio is 21.02. In terms of profitability, MEDOF's ROE is +0.04%, compared to AMFPF's ROE of +0.09%. Regarding short-term risk, MEDOF is more volatile compared to AMFPF. This indicates potentially higher risk in terms of short-term price fluctuations for MEDOF.Check AMFPF's competition here
MEDOF vs ARHCF Comparison April 2026
MEDOF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDOF stands at 1.2B. In comparison, ARHCF has a market cap of 2.2B. Regarding current trading prices, MEDOF is priced at $50.00, while ARHCF trades at $11.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDOF currently has a P/E ratio of 73.53, whereas ARHCF's P/E ratio is 9.97. In terms of profitability, MEDOF's ROE is +0.04%, compared to ARHCF's ROE of +0.07%. Regarding short-term risk, MEDOF is more volatile compared to ARHCF. This indicates potentially higher risk in terms of short-term price fluctuations for MEDOF.Check ARHCF's competition here
MEDOF vs SZUKF Comparison April 2026
MEDOF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDOF stands at 1.2B. In comparison, SZUKF has a market cap of 1.7B. Regarding current trading prices, MEDOF is priced at $50.00, while SZUKF trades at $30.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDOF currently has a P/E ratio of 73.53, whereas SZUKF's P/E ratio is 11.43. In terms of profitability, MEDOF's ROE is +0.04%, compared to SZUKF's ROE of +0.09%. Regarding short-term risk, MEDOF is more volatile compared to SZUKF. This indicates potentially higher risk in terms of short-term price fluctuations for MEDOF.Check SZUKF's competition here
MEDOF vs IUSDF Comparison April 2026
MEDOF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDOF stands at 1.2B. In comparison, IUSDF has a market cap of 997.7M. Regarding current trading prices, MEDOF is priced at $50.00, while IUSDF trades at $14.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDOF currently has a P/E ratio of 73.53, whereas IUSDF's P/E ratio is 18.18. In terms of profitability, MEDOF's ROE is +0.04%, compared to IUSDF's ROE of +0.13%. Regarding short-term risk, MEDOF is more volatile compared to IUSDF. This indicates potentially higher risk in terms of short-term price fluctuations for MEDOF.Check IUSDF's competition here
MEDOF vs ARRJF Comparison April 2026
MEDOF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDOF stands at 1.2B. In comparison, ARRJF has a market cap of 807.6M. Regarding current trading prices, MEDOF is priced at $50.00, while ARRJF trades at $2.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDOF currently has a P/E ratio of 73.53, whereas ARRJF's P/E ratio is 21.18. In terms of profitability, MEDOF's ROE is +0.04%, compared to ARRJF's ROE of +0.05%. Regarding short-term risk, MEDOF is more volatile compared to ARRJF. This indicates potentially higher risk in terms of short-term price fluctuations for MEDOF.Check ARRJF's competition here
MEDOF vs EXHI Comparison April 2026
MEDOF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDOF stands at 1.2B. In comparison, EXHI has a market cap of 16M. Regarding current trading prices, MEDOF is priced at $50.00, while EXHI trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDOF currently has a P/E ratio of 73.53, whereas EXHI's P/E ratio is N/A. In terms of profitability, MEDOF's ROE is +0.04%, compared to EXHI's ROE of +0.00%. Regarding short-term risk, MEDOF is more volatile compared to EXHI. This indicates potentially higher risk in terms of short-term price fluctuations for MEDOF.Check EXHI's competition here
MEDOF vs PDRX Comparison April 2026
MEDOF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDOF stands at 1.2B. In comparison, PDRX has a market cap of 5.7M. Regarding current trading prices, MEDOF is priced at $50.00, while PDRX trades at $3.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDOF currently has a P/E ratio of 73.53, whereas PDRX's P/E ratio is 3.10. In terms of profitability, MEDOF's ROE is +0.04%, compared to PDRX's ROE of -0.02%. Regarding short-term risk, MEDOF is more volatile compared to PDRX. This indicates potentially higher risk in terms of short-term price fluctuations for MEDOF.Check PDRX's competition here
MEDOF vs NSVGF Comparison April 2026
MEDOF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDOF stands at 1.2B. In comparison, NSVGF has a market cap of 3.3M. Regarding current trading prices, MEDOF is priced at $50.00, while NSVGF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDOF currently has a P/E ratio of 73.53, whereas NSVGF's P/E ratio is -1.00. In terms of profitability, MEDOF's ROE is +0.04%, compared to NSVGF's ROE of +0.21%. Regarding short-term risk, MEDOF is more volatile compared to NSVGF. This indicates potentially higher risk in terms of short-term price fluctuations for MEDOF.Check NSVGF's competition here
MEDOF vs KOSK Comparison April 2026
MEDOF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDOF stands at 1.2B. In comparison, KOSK has a market cap of 1.8M. Regarding current trading prices, MEDOF is priced at $50.00, while KOSK trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDOF currently has a P/E ratio of 73.53, whereas KOSK's P/E ratio is -0.28. In terms of profitability, MEDOF's ROE is +0.04%, compared to KOSK's ROE of -0.12%. Regarding short-term risk, MEDOF is more volatile compared to KOSK. This indicates potentially higher risk in terms of short-term price fluctuations for MEDOF.Check KOSK's competition here
MEDOF vs ITNS Comparison April 2026
MEDOF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDOF stands at 1.2B. In comparison, ITNS has a market cap of 761.7K. Regarding current trading prices, MEDOF is priced at $50.00, while ITNS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDOF currently has a P/E ratio of 73.53, whereas ITNS's P/E ratio is -0.05. In terms of profitability, MEDOF's ROE is +0.04%, compared to ITNS's ROE of +0.01%. Regarding short-term risk, MEDOF is more volatile compared to ITNS. This indicates potentially higher risk in terms of short-term price fluctuations for MEDOF.Check ITNS's competition here
MEDOF vs CHME Comparison April 2026
MEDOF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDOF stands at 1.2B. In comparison, CHME has a market cap of 474.2K. Regarding current trading prices, MEDOF is priced at $50.00, while CHME trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDOF currently has a P/E ratio of 73.53, whereas CHME's P/E ratio is -2.00. In terms of profitability, MEDOF's ROE is +0.04%, compared to CHME's ROE of +0.04%. Regarding short-term risk, MEDOF is more volatile compared to CHME. This indicates potentially higher risk in terms of short-term price fluctuations for MEDOF.Check CHME's competition here
MEDOF vs ENMI Comparison April 2026
MEDOF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDOF stands at 1.2B. In comparison, ENMI has a market cap of 383.1K. Regarding current trading prices, MEDOF is priced at $50.00, while ENMI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDOF currently has a P/E ratio of 73.53, whereas ENMI's P/E ratio is -0.01. In terms of profitability, MEDOF's ROE is +0.04%, compared to ENMI's ROE of +0.17%. Regarding short-term risk, MEDOF is more volatile compared to ENMI. This indicates potentially higher risk in terms of short-term price fluctuations for MEDOF.Check ENMI's competition here
MEDOF vs PHRX Comparison April 2026
MEDOF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDOF stands at 1.2B. In comparison, PHRX has a market cap of 5.2K. Regarding current trading prices, MEDOF is priced at $50.00, while PHRX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDOF currently has a P/E ratio of 73.53, whereas PHRX's P/E ratio is N/A. In terms of profitability, MEDOF's ROE is +0.04%, compared to PHRX's ROE of +0.85%. Regarding short-term risk, MEDOF is less volatile compared to PHRX. This indicates potentially lower risk in terms of short-term price fluctuations for MEDOF.Check PHRX's competition here
MEDOF vs MLTO Comparison April 2026
MEDOF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDOF stands at 1.2B. In comparison, MLTO has a market cap of 1.7K. Regarding current trading prices, MEDOF is priced at $50.00, while MLTO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDOF currently has a P/E ratio of 73.53, whereas MLTO's P/E ratio is -0.00. In terms of profitability, MEDOF's ROE is +0.04%, compared to MLTO's ROE of N/A. Regarding short-term risk, MEDOF is less volatile compared to MLTO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDOF.Check MLTO's competition here
MEDOF vs TGVN Comparison April 2026
MEDOF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDOF stands at 1.2B. In comparison, TGVN has a market cap of 120. Regarding current trading prices, MEDOF is priced at $50.00, while TGVN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDOF currently has a P/E ratio of 73.53, whereas TGVN's P/E ratio is -0.00. In terms of profitability, MEDOF's ROE is +0.04%, compared to TGVN's ROE of N/A. Regarding short-term risk, MEDOF is more volatile compared to TGVN. This indicates potentially higher risk in terms of short-term price fluctuations for MEDOF.Check TGVN's competition here